






The Determination of Breath Biomarkers for Disease and Health Identifiers to Create a Non-Invasive Rapid Screen using Portable Mass Spectrometry



Dr. Guido F. Verbeck

Departments: Chemistry and Biological Sciences









INFICON

PFEIFFER VACUUM




U.S. ARMY

Mach, P.M.; McBride, E.M.; Sasiene, Z.J.; Brigance, K.R.; Kennard, S.K.; Wright, K.C.; Verbeck, G.F., "Vehicle-Mounted Portable Mass Spectrometry System for the Covert Detection via Spatial Analysis of Clandestine Methamphetamine Laboratories", *Anal. Chem.*, 87 (2015) 11501-11508








Addition of NaBH_4





Final Product






aniline










INFICON
PFEIFFER VACUUM

Mach, P.M.; Winfield, J.L.; Aquilar, R.A.; Wright, K.C.; Verbeck, G.F., "A Portable Mass Spectrometer Study Targeting Anthropogenic Contaminants in Sub-Antarctic Puerto Williams, Chile" *Int. J. Mass Spectrom.* 422 (2017) 148-153.



MIMS System Flat Membrane Analysis (cont.)








Figure 1. CAD drawing for the Portable Mass Spectrometer drone system




Figure 2. CAD drawing for the Portable Mass Spectrometer drone system analyzing smoke chemistry







 **crux**






 **crux**













Chemistry at the True One-Cell Limit









(a) Mass spectrum of the 51 carbon TAG range obtained from nanoextraction of the lipid droplet shown in (c) using NSI in a linear ion trap mass spectrometer with ammonium adduct $[M+NH_4]^+$. (b) Mass spectrum from nanoextraction of the lipid droplet shown in (d) from MALDI in a hybrid linear ion trap-orbitrap mass spectrometer with sodium adduct $[M+Na]^+$. Images are 40x differential interference contrast with scale bar of $50 \mu m$.

Breast Tissue: Extraction of Lipid Body




A. Healthy

Emitter tip (a) entering lipid body (b).



B. Tumor


Emitter tip (a) entering lipid body (b) within surrounding cancerous cells (c).



■ Healthy F'14
■ Tumor F'14

Breast Tissue: Heterogeneity of the Relative Triglyceride Distribution

**Paper Spray Mass spectrometry utilizing
Teslin® substrate for rapid detection of lipid
metabolite changes during COVID-19
infection**



Rapid detection of lipid metabolite changes during COVID-19 infection


Current testing methods

- ✓ Polymerase Chain Reaction (PCR)- current viral infection
- ✓ Antibody test - previous infection (1-3 weeks to produce antibodies)
- ✓ Negative identification is still vulnerable- Antibody test

Challenges

- Complexity
- Time
- Backlog of testing kits
- The cost of testing
- Risk with considerable uncertainty
- cross-contamination
- carryover contamination
- mutation of the primer
- improper sampling procedures and handling

The life cycle of SARS-COV2 and potential lipid modification




Abu-Farha, Mohamed et al. "The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target." International journal of molecular sciences vol. 21,10 3544. 17 May. 2020, doi:10.3390/ijms21103544

Overall Mass range 50m/z-1000m/z


- Sample A6 +ve
- Sample A7 +ve
- Sample 12 +ve
- Sample A1 -ve
- sample A2 -ve
- Sample A3 -ve
- Sample A4 -ve
- Sample 8 -ve
- Sample A11 +ve
- Sample A5 +ve

COVID positive samples

COVID negative samples






Rapid detection of lipid metabolite changes during COVID-19 infection




Sample Retrieval and preparation

De Silva, I. W.; Nayek, S.; Singh, V.; Reddy, J.; Granger, J. K.; Verbeck, G. F., Paper spray mass spectrometry utilizing Teslin® substrate for rapid detection of lipid metabolite changes during COVID-19 infection. *Analyst* 2020





Rapid detection of lipid metabolite changes during COVID-19 infection



De Silva, I. W.; Nayek, S.; Singh, V.; Reddy, J.; Granger, J. K.; Verbeck, G. F., Paper spray mass spectrometry utilizing Teslin® substrate for rapid detection of lipid metabolite changes during COVID-19 infection. *Analyst* **2020**

[M+H] ⁺	m/z shown in the paper	Metabolite Name	CAS ID	Metabolite ID
92.0219	92	*Aminooxyacetic Acid	645-88-5	N/A
92.9862	93	*Hydroxyethyl methyl sulfide	5271-38-5	HMDB0032425
95.9931	96	*3-Hydroxypyridine	109-00-2	N/A
98.0835	98	*N-Pyrrylcarbinol	92776-61-9	N/A
108.0246	108	*Benzylamine	100-46-9	HMDB0033871
140.0816	140	*3-Hydroxypicolinic acid	874-24-8	HMDB0013188
175.0003	175	*Glycerol-3-Phosphate +2H	Oxidized form 57-03-4	Oxidized form HMDB0000126
284.0727	284	* Linoleamide +4H	Oxidized form 3072-13-7	Oxidized form HMDB0062656
296.1589	296	* Linoleamide +O	Oxidized form 3072-13-7	Oxidized form HMDB0062656
306.8391	306	*Arachidonic acid +2H	Oxidized form 506-32-1	Oxidized form HMDB0001043
539.151	539	*LPE (0:0/20:2) +OOH	N/A	HMDB0011513



Rapid detection of lipid metabolite changes during COVID-19 infection



De Silva, I. W.; Nayek, S.; Singh, V.; Reddy, J.; Granger, J. K.; Verbeck, G. F., Paper spray mass spectrometry utilizing Teslin® substrate for rapid detection of lipid metabolite changes during COVID-19 infection. *Analyst* 2020

discriminant function 1

$$= 1.5 * (m/z92) - 2.66 * (m/z93) - 1.94 * (m/z96) + 2.07 (m/z98) - 1.1 (m/z108) + 1.12(m/z140) - 2.22 (m/z175) + 2.77 (m/z257) + 6.41(m/z296) + 5.11(m/z307) - 0.14(m/z539)$$





discriminant function 2

$$= 0.12 * (m/z92) + 0.78(m/z93) - 1.24 * (m/z96) - 0.76(m/z98) + 0.74(m/z108) - 0.56(m/z140) + 0.10(m/z175) + 0.36 (m/z257) - 0.96(m/z296) + 1.05(m/z307) + 0.76(m/z539)$$







C Summary of PS-MS Classification

Sample Number	PCR Confirmation	PS-MS Classification (Function2)
Positive 1	COVID-19 Positive	● 2.380 Positive
Positive 2	COVID-19 Positive	● 2.780 Positive
Positive 3	COVID-19 Positive	● 2.390 Positive
Positive 4	COVID-19 Positive	● 2.960 Positive
Positive 5	COVID-19 Positive	● 1.330 Positive
Positive 6	COVID-19 Positive	● -0.650 Negative
Positive 7	COVID-19 Positive	● 0.550 Positive
Positive 8	COVID-19 Positive	● 2.260 Positive
Positive 9	COVID-19 Positive	● 3.040 Positive
Positive 10	COVID-19 Positive	● 1.820 Positive
Negative 1	COVID-19 Negative	● -3.310 Negative
Negative 2	COVID-19 Negative	● -1.470 Negative
Negative 3	COVID-19 Negative	● -1.970 Negative
Negative 4	COVID-19 Negative	● -1.930 Negative
Negative 5	COVID-19 Negative	● -2.460 Negative
Negative 6	COVID-19 Negative	● -0.540 Negative
Negative 7	COVID-19 Negative	● -1.540 Negative
Negative 8	COVID-19 Negative	● -0.070 Negative
Negative 9	COVID-19 Negative	● -2.560 Negative
Negative 10	COVID-19 Negative	● -1.650 Negative
Blind1	COVID-19 Negative	● -0.180 Negative
Blind2	COVID-19 Negative	● -1.760 Negative
Blind3	COVID-19 Negative	● -0.800 Negative
Blind4	COVID-19 Negative	● -0.650 Negative
Blind5	COVID-19 Negative	● -0.240 Negative
Blind6	COVID-19 Positive	● 0.910 Positive
Blind7	COVID-19 Positive	● 0.220 Positive
Blind8	COVID-19 Positive	● 0.240 Positive
Blind9	COVID-19 Positive	● -0.260 Negative
Blind10	COVID-19 Positive	● 1.000 Positive



COVID positive samples



COVID negative samples

Unique Peaks common in $\geq 20\%$ and $\geq 10\%$ of spectra: Positive Cases (without Positive Case 1) and Negative cases

Unique Positive Peak(s) NOT including sample one ($\geq 10\%$)		Unique Negative Peak(s) ($\geq 10\%$)
m/z	m/z	m/z
65	294	181
83	295	
87	299	
96	301	
97	315	
115	316	
117	331	
141	333	
142	345	
143	352	
157	353	
165	360	
202	361	
225	371	
227	383	
235	408	
247		

Unique Positive Peak(s) NOT including sample one ($\geq 20\%$)	Unique Negative Peak(s) ($\geq 20\%$)
m/z	m/z
83	none
87	
115	
117	
141	
143	
165	
225	
294	
301	
408	

Average Relative Intensities of Unique Peaks common in $\geq 10\%$ of spectra: Positive Cases (without case 1) and Negative cases

Average Relative Intensity of Unique Negative Peaks ($\geq 10\%$)	
m/z	Average Relative Intensity
181	18.28

- No matching duplicates between positive case 1 and positive cases 2 – 5.

Average Relative Intensity of Unique Positive Peaks NOT including sample one ($\geq 10\%$)			
m/z	Average Relative Intensity	m/z	Average Relative Intensity
65	15.75	294	45.85
83	69.92	295	13.53
87	86.74	299	22.04
96	20.37	301	27.09
97	18.02	315	35.82
115	98.91	316	16.63
117	41.81	331	11.89
141	43.18	333	17.38
142	21.70	345	25.82
143	61.94	352	37.64
157	20.44	353	17.01
165	47.48	360	19.79
202	17.77	361	14.74
225	32.08	371	26.80
227	15.32	383	11.96
235	13.37	408	42.52
247	13.14		










0.5ppb Concentration Acquisition

Standard Compounds: Aldehydes& Ketones



1. Formaldehyde: **29 m/z**
 2. Acetaldehyde: **29 m/z** (**15 m/z**)
 3. Acrolein: **56 m/z**
 4. Acetone: **43 m/z**
 5. Propionaldehyde: **58 m/z**
 6. Crotonaldehyde: **41 m/z**
 7. Butyraldehyde: **44 m/z**
 8. Benzaldehyde: **77 m/z**
 9. Isovaleraldehyde: **44 m/z** (**27 m/z**)
 10. Valeraldehyde: **44 m/z** (**57 m/z**)
 11. o-Tolualdehyde: **91 m/z**
 12. m-Tolualdehyde: **91 m/z**
 13. p-Tolualdehyde: **91 m/z**
 14. Hexanal: **44 m/z** (**39 m/z**)
 15. 2,5-Dimethylbenzaldehyde: **134 m/z**
- RED** = Parent peak
BLACK = Daughter peak
BOLD = Tracked m/z value

Breathalyzer Portable Mass Spectrometry





INSPECT
SYSTEMS, LLC
Accountability Begins With Measurement





UNT
UNIVERSITY OF NORTH TEXAS







0.5ppb Concentration Acquisition VS Background Acquisition



0.5ppb Concentration Acquisition



0.5ppb Concentration Acquisition





Verbeck Research Group

Guido Verbeck, Ph.D.*
 Imesha De Silva
 Rachel Koerber

Tom Kiselak
 Subhayu Nayek
 Camila Anguiano Virgen



SK Challenge Team

Guido Verbeck, Ph.D.*
 JD Fox, Ph.D.
 Pierre Wellner, Ph.D.

Camila Anguiano Virgen

Ken Wright, Ph.D.
 Jamie Winfield
 Peter Santariello




DEPARTMENT OF
 CHEMISTRY
 College of Science
UNT
 EST. 1890



CANCER PREVENTION &
 RESEARCH INSTITUTE OF TEXAS





Verbeck Research Group

Guido Verbeck, Ph.D.* Phillip Mach, Ph.D.
 Roberto Aguilar, Ph.D. Ethan McBride, Ph.D.
 Jason Hamilton, Ph.D.



Chile Team

Guido Verbeck, Ph.D.* Ken Wright, Ph.D.
 Philip Mach, Ph.D. Roberto Aguilar, Ph.D.



DEPARTMENT OF
 CHEMISTRY
 College of Science
UNT
 EST. 1890



CANCER PREVENTION &
 RESEARCH INSTITUTE OF TEXAS

